EVH Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -4.35% compared to Evolent Health, Inc.'s net margin of 0.11%. Evolent Health, Inc.'s return on equity of -13.6% beat Astrana Health, Inc.'s return on equity of 1.85%.

Evolent Health, Inc. has a consensus price target of $9.60, signalling upside risk potential of 186.04%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 62.22%. Given that Evolent Health, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Evolent Health, Inc. is more attractive than Astrana Health, Inc..

Evolent Health, Inc. has a beta of 0.256, which suggesting that the stock is 74.427% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

Evolent Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health, Inc. pays 32.59% of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolent Health, Inc. quarterly revenues are $479.5M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Evolent Health, Inc.'s net income of -$20.9M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Evolent Health, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 119.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health, Inc. is 0.18x versus 0.38x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of -4.35% compared to Evolent Health, Inc.'s net margin of 9.58%. Evolent Health, Inc.'s return on equity of -13.6% beat Cryo-Cell International, Inc.'s return on equity of --.

Evolent Health, Inc. has a consensus price target of $9.60, signalling upside risk potential of 186.04%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 156.02%. Given that Evolent Health, Inc. has higher upside potential than Cryo-Cell International, Inc., analysts believe Evolent Health, Inc. is more attractive than Cryo-Cell International, Inc..

Evolent Health, Inc. has a beta of 0.256, which suggesting that the stock is 74.427% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.12%.

Evolent Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 19.58% to investors and pays a quarterly dividend of $0.15 per share. Evolent Health, Inc. pays 32.59% of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International, Inc.'s is not.

Evolent Health, Inc. quarterly revenues are $479.5M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Evolent Health, Inc.'s net income of -$20.9M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Evolent Health, Inc.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health, Inc. is 0.18x versus 0.85x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teladoc Health, Inc. has a net margin of -4.35% compared to Evolent Health, Inc.'s net margin of -7.9%. Evolent Health, Inc.'s return on equity of -13.6% beat Teladoc Health, Inc.'s return on equity of -15.44%.

Evolent Health, Inc. has a consensus price target of $9.60, signalling upside risk potential of 186.04%. On the other hand Teladoc Health, Inc. has an analysts' consensus of $8.93 which suggests that it could grow by 63.89%. Given that Evolent Health, Inc. has higher upside potential than Teladoc Health, Inc., analysts believe Evolent Health, Inc. is more attractive than Teladoc Health, Inc..

Evolent Health, Inc. has a beta of 0.256, which suggesting that the stock is 74.427% less volatile than S&P 500. In comparison Teladoc Health, Inc. has a beta of 2.040, suggesting its more volatile than the S&P 500 by 103.96%.

Evolent Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teladoc Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health, Inc. pays 32.59% of its earnings as a dividend. Teladoc Health, Inc. pays out -- of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolent Health, Inc. quarterly revenues are $479.5M, which are smaller than Teladoc Health, Inc. quarterly revenues of $626.4M. Evolent Health, Inc.'s net income of -$20.9M is higher than Teladoc Health, Inc.'s net income of -$49.5M. Notably, Evolent Health, Inc.'s price-to-earnings ratio is -- while Teladoc Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health, Inc. is 0.18x versus 0.38x for Teladoc Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.